UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number,
including area code: (
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 1.01 | Entry into a Material Definitive Agreement |
On May 15, 2023, Coherus BioSciences, Inc. (the “Company”) previously announced that it reduced the amount of shares that could be issued and sold pursuant to its “at-the-market” program (“ATM”) with Cowen and Company, LLC (“TD Cowen”) in an amount equal to $86.25 million. The reduction in the amount of shares that could be issued and sold was effected pursuant to the Amendment No. 1 to Sales Agreement (“Amendment No. 1”), which amended the Company’s Sales Agreement with TD Cowen, dated November 8, 2022 (the “Agreement”), to reduce the aggregate offering price under the Agreement from $150.0 million to $63.75 million.
On September 11, 2023, the Company increased the amount of shares that could be issued and sold pursuant to its ATM with TD Cowen in an amount equal to $28.75 million. The increase in the amount of shares that can be issued and sold under the ATM was effected pursuant to the Amendment No. 2 to Sales Agreement (“Amendment No. 2”), which amended the Agreement, as previously amended by Amendment No. 1, to increase the aggregate offering price under the Agreement from $63.75 million to $92.5 million.
The foregoing descriptions of Amendment No. 1 and Amendment No. 2 are not complete descriptions thereof, and are qualified in their entirety by reference to the full text of Amendment No. 1, which was filed with the Securities and Exchange Commission as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2023, and Amendment No. 2, which will be filed with the Securities and Exchange Commission as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2023.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: September 11, 2023 | COHERUS BIOSCIENCES, INC. | |
| By: | /s/ McDavid Stilwell | |
| Name: | McDavid Stilwell | |
| Title: | Chief Financial Officer | |